A new study analyzing data from the UK Biobank finds that accelerated biological aging, measured by Phenotypic Age (PhenoAge), is strongly associated with mortality risk in individuals with Parkinson’s disease (PD). The findings position PhenoAge as a potentially valuable clinical tool for identifying high-risk patients and guiding personalized interventions.

Biological aging clocks, including Phenotypic Age, are increasingly used to estimate an individual’s biological age based on measurable biomarkers. While such clocks have been widely adopted over the past two decades, researchers emphasize that much remains unknown about how accurately these measures reflect underlying aging processes, or how reliably they can assess the impact of emerging age-slowing or age-reversing therapies. In this context, expanding the evidence base linking clock outputs to meaningful clinical outcomes, such as disease risk and mortality, is considered a critical step forward.

To explore the prognostic relevance of biological aging in Parkinson’s disease, investigators examined data from 569 PD patients enrolled in the UK Biobank. Using Cox regression modeling, the team identified independent risk factors for mortality and developed a predictive nomogram to estimate survival outcomes.

The analysis revealed that both Phenotypic Age (PhenoAge) and Phenotypic Age Acceleration (PhenoAgeAccel) significantly influenced survival in PD patients. Independent predictors of mortality included:

• Chronological age
• Male sex
• Smoking status
• Underweight status
• Depressive mood
• Low-density lipoprotein levels
• Elevated genetic susceptibility

Notably, the nomogram constructed using PhenoAge demonstrated strong predictive performance for mortality risk.

Researchers conclude that PhenoAge may serve as a pivotal predictor of mortality in Parkinson’s disease, enabling clinicians to identify patients experiencing accelerated biological aging. Such insights could support earlier, more targeted interventions aimed at improving outcomes in this vulnerable population.

While questions remain about how biological aging clocks map onto the fundamental mechanisms of aging, studies like this help clarify their real-world clinical relevance. As the field advances, continued data collection and outcome-based validation will be essential to determine how best to integrate aging biomarkers into therapeutic development and patient care.